January 8th 2021
Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.
December 15th 2020
TP53-mutant myelodysplastic syndromes and acute myeloid leukemia represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival.
December 2nd 2020
Joseph G. Jurcic, MD, discusses strategies to optimize patient selection for luspatercept in MDS.
November 19th 2020
The first biomarker-drive intervention for patients with non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation is now available in clinical practice.
November 13th 2020
Patients on active therapy during the coronavirus disease 2019 pandemic, as well as oncology care providers, have increased levels of perceived and posttraumatic stress, according to preliminary data from the COVIPACT study.
November 12th 2020
TP53-targeted treatment options represent an unmet need for patients with myelodysplastic syndromes and acute myeloid leukemia.
November 11th 2020
Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.
October 14th 2020
Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.
October 8th 2020
Gilead Sciences’ acquisition of Immunomedics, the manufacturer of sacituzumab govitecan-hziy, is expected to advance the development of the antibody-drug conjugate not only across additional types of breast cancer beyond triple-negative disease, but also in other solid tumors.